Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-analysis

Zhihan Gao (gaozhihanhz@163.com)  
Hangzhou Geriatric Hospital

Fengli Sun  
Zhejiang Province mental health Center

Wangqiang Lv  
jinhua Second hospital

Dong Shen  
Jiaxing Kangci Hospital

Weidong Jin  
Zhejiang Chinese Medical University

Primary research

Keywords: Lamotrigine, Lithium, Combination therapy, RCBD, Bipolar disorder

Posted Date: August 10th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-786518/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

**Objective:** to observe effect of combination of lithium and lamotrigine in treatment for Rapid-cycling bipolar disorder (RCBD).

**Method:** We searched both MEDLINE, EMBASE, Cochrane Library in English and CBM, CNKI, WANFANG and CSSCI in Chinese to find literature from January 1 2000 to December 31, 2020 related to combination of lithium carbonate and lamotrigine for treatment of RCBD.

**Results:** Five comparison studies, with 265 subjects of 131 cases in study group and 134 cases in control group met the inclusion criteria and were included for the final meta-analysis. The comprehensive analysis show that study group had significant lower score of mental symptoms than that of control group ($Z=2.34$, $P=0.02$) by random model ($X^2=33.02$, $df=7$, $P<0.01$). But these differences only were shown in PANSS ($Z=5.18$, $P<0.01$) and BPRS ($Z=3.08$, $P<0.01$). The no difference in response rate ($54.9\%$ vs $45.7\%$, OR=$1.47$, 95% CI: 0.79$–$2.73$, $Z=1.21$, $P>0.05$), and remission rate ($47.9\%$ vs $45.9\%$, OR=$1.05$, 95% CI: 0.49$–$2.25$, $Z=0.13$, $P>0.05$), were found between two groups. The response rate of lamotrigine and lithium combination was significant higher compare to monotherapy of lithium in patients with no treatment-resistant ($82\%$ vs $54\%$, OR=$4.26$, 95% CI: $1.65$–$10.99$, $Z=3.99$, $P<0.01$) by fixed effect model ($X^2=0.89$, $df=1$, $P>0.05$, $I^2=0\%$).

**Conclusion:** Combination of lithium and lamotrigine have better improvement of psychotic symptoms and higher response rate in patients of RCBP with no treatment-resistant.

Background

Long-term course of bipolar disorder is typified by recurring mood episodes of opposite polarity as well as mixed states. Rapid-cycling bipolar disorder refers to the presence of at least 4 mood episodes in the previous 12 months that meet the criteria for manic, hypomanic, or major depressive episode[1]. The rapid cycling were also conclude ultra-rapid (cycle lengths of days to weeks, including 48-h cycling) and and ultra-ultra-rapid cycling (cycle lengths up to 24 h) according the cycling speed[2,3,4]. But the course is not clear, and antidepressant maybe a extra induced course[2,5]. Rapid-cycling bipolar disorder (RCBD) has been estimated to affect approximately 20% of patients with bipolar disorders[6]. Patients with RCBD are more likely to demonstrate non-response to traditional mood stabilizers and have a poorer prognosis and an increased risk for suicide compared to those without RCBD[7]. Moreover, frequent comorbidities with substance use disorders pose additional negative impact on the treatment outcomes of patients with RCBD, including a greater risk for treatment nonadherence, more hospitalizations more mood episodes lower rates of remission, 13 and decreased quality of life[6]. So most guide about treatment rapid cycling bipolar disorder all suggest stop and prohibit usage of antidepressant, and suggest combination of mood stabilizer.

Lamotrigine is a mood stabilizer; it also is a first line option in the acute and maintenance treatment of bipolar disorder, and only one drug called “mood stabilizer for depression” to used often in bipolar disorder because there is a high prevalence of depression among BD affected individuals[8]. A meta-analytically summarize lamotrigine's effectiveness and safety in unipolar and bipolar depression and found that lamotrigine outperformed placebo regarding depressive symptoms (studies = 11, $n = 713$ vs $n = 696$; SMD = -0.15, 95% CI = -0.27, -0.02, $p = 0.02$, heterogeneity: $p = 0.24$) and response (after removing one extreme outlier; RR = 1.42, 95% CI = 1.13–1.78; $p = 0.003$, heterogeneity: $p = 0.08$). Conversely, lamotrigine did not differ regarding efficacy on depressive symptoms, response, or remission from lithium, olanzapine + fluoxetine, citalopram, or inositol (studies = 6, $n = 306$ vs $n = 318$, p-values = 0.85–0.92)[9]. So lamotrigine was superior to placebo in improving unipolar and bipolar depressive symptoms, without causing more frequent
adverse effects/discontinuations and did not differ from lithium, olanzapine + fluoxetine, citalopram, or inositol. The lamotrigine was used more and more in treatment of bipoar depression.

Lithium is a first line option in the acute and maintenance treatment of bipolar disorder, and only one drug that can prevent suicide because there is a high suicidal risk among BD affected individuals. But this is not only one ration that lithium was used in bipolar disorder. The lithium of choice in treatment of this disorder with special emphasis on pharmacology, and it have both effectiveness in depression and mania. These alternatives should be potent mood stabilizers as monotherapy so as to avoid polypharmacy[8]. But the fact is that polypharmacy for bipolar treatment are more often,especially for rapid cycling bipolar disorder.

The concept of double mood stabilizer have been suggested for treatment bipolar disorder[11,12,13].The clinical therapeutic effect is more than that only one mood stabilizer for patients with bipolar disorder with less interaction between drugs.But this is combination of lithium and valproate,which was more common than that of lithium and lamortigine.However, lamotrigine is called “mood stabilizer for depression” and also can decrease the switch to mania induced by antidepressant[8,14],which may further strengthen the mood stability of lithium to improve depression symptom that were less likely to respond to the treatment of single lithium or divalproex. And the study also shown that lamotrigine is superior to placebo in treatment of rapid cycling bipolar disorder[15]. Case report addition of lamotrigine to valproic acid had a successful outcome in a case of rapid-cycling bipolar affective disorder[16].So their combination may play a role on bipolar disorder,especially on rapid cycling bipolar disorder.

Methods

1. Literature retrieval methods:

1.1 This study was performed according to the recommendations of the Moose [17]. Two reviewers independently searched the database. The database includes all Chinese databases: Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), WANFANG and Chinese Social Sciences Citation Index (VIP) databases.

1.2 Search key words: lamotrigine, lithium, bipolar disorder, rapid cycling. Their retrieved relationship is “lamotrigine” and “lithium”, and “bipolar disorder” and “rapid cycling.”

1.3 The search strategy: The search strategy was based on combinations. To retrieved all articles, we search papers by “lamotrigine and lithium and bipolar disorder (or mood disorder or mania or bipolar depression or depression)”, And then further screen the papers related by add “rapid cycling”. Last query was updated on Juan 1 2000 to Juan 1 2021. References of retrieved articles were cross-searched to identify any studies missed by the electronic search strategies. see Fig. 1.

1.4 Inclusion and Exclusion Criteria

The two researchers reviewed the initial retrieved publications independently. The discrepancy was resolved through discussion by all reviewers. Studies that met the following criteria were included: (1) study about combination of lamotrigine and lithium for treatment of rapid cycling bipolar disorder. (2) study design was combination of lamotrigine and lithium compared to only lithium. (3) there was index of therapeutic effects in study design. However, articles had incomplete or unidentified data were excluded, as well as abstracts, reviews, case reports, letters and duplicate publications.
1.5 Two psychiatrists reviewed each included article independently, using the 11-item checklist that was recommended by the Agency for Healthcare Research and Quality (AHRQ) [18]. An item would be scored ‘0’ if it was answered ‘NO’ or ‘UNCLEAR’ whereas ‘1’ will be given to the answer ‘YES’. Article quality was assessed as follows: low quality = 0–3; moderate quality = 4–7; high quality = 8–11. Differences in article quality were discussed to reach an agreeable final score. The following information was extracted: first author, publication time, the sample size, study population, assessment tools, and index of therapeutic effects. See Table 1[6,7,19,20,21]. See Table 1.

1.6 Statistic analysis: All statistical analyses were performed using software of Revman 5.2, and the P value for the overall effect < 0.05 with two-tailed was considered statistically significant. The heterogeneity of all involved studies was assessed by $I^2$. When it was lower than 50%, the studies with an acceptable heterogeneity were considered, and then the fixed-effects model with Mantel-Haenszel method was used; otherwise, a random effect model with the DerSimonian and Laird (DL) method was adopted.

1.7 Assessment of publication bias was investigated for each of the pooled study groups mainly by the Egger’s linear regression test. As supplement approach, the Begg’s rank correlation also was applied to assess the potential publication bias.

Results

1. Study Characteristic

Five comparison studies, with with 265 subjects of 131 cases in study group and 134 cases in control group, who met the inclusion criteria and were included for the final meta-analysis. Five studies consist of 3 study in Chinese and 2 in English[5,25 ~ 38]. The sample size of the studies ranged from 18 to 40. Assessment tools for therapeutic effectiveness used in the studies are list as follows: PANSS, BPRS, YMRS, MARDS, CGI. The main features of the 5 articles were summarized in Table 1. AHRQ scores suggested that all 5 studies scored at eight as high quality.

2. Comparison of mental symptoms between study and control group.

The scale assessment for mental symptom during treatment were sued in 4 studies. The PANSS and BPRS was used in 2 studies, YMRS and MARDS was used in other studies. The subgroup analysis was made for mental symptom due to the different way of assessment. The comprehensive analysis show that study group had significant lower score of mental symptoms than that of control group ($Z = 2.34, P = 0.02$) by random model($X^2 = 33.02, df = 7, P < 0.01$). But these differences only were shown in PANSS($Z = 5.18, P < 0.01$) and BPRS($Z = 3.08, P < 0.01$), not shown in MADRS($Z = 0.39, P > 0.05$) and YMRS($Z = 0.94, P > 0.05$). See Fig. 2. But the publishing bias was found by the funnel plot analysis, see Fig. 3.

3. Comparison of response and remission between study group and control group.

4 of the 5 studies with 185 subjects were included for the meta-analysis of response rate, which was 54.9% in study group and 45.7% in control group. The random effect model was used for this analysis($X^2 = 13.02, df = 3, P < 0.01, I^2 = 77$%). The no difference in response rate was found between two groups($OR = 1.47, 95\% CI: 0.79 \sim 2.73, Z = 1.21, P > 0.05$). See Fig. 4.

3 of the 5 studies with 145 subjects were included for the meta-analysis of remission rate, which was 47.9% in study group and 45.9% in control group. The random effect model was used for this analysis($X^2 = 4.42, df = 2, P > 0.05, I^2 = 55$%). The no difference in remission rate was found between two groups($OR = 1.05, 95\% CI: 0.49 \sim 2.25, Z = 0.13, P > 0.05$). See Fig. 5.
Subgroup meta-analysis for response rate also was made according to treatment-resistant or not. The response rate of lamotrigine and lithium combination was significant higher compare to monotherapy of lithium in patients with no treatment-resistant (82% V 54%, OR = 4.26, 95% CI: 1.65 ~ 10.99, Z = 3.99, P < 0.01) by fixed effect model ($X^2 = 0.89, df = 1, P > 0.05, I^2 = 0$%). But the response rate of lamotrigine, lithium and valprorate combination was not significant higher compare to placebo, lithium and valprorate combination in patients with treatment-resistant (21.9% V 36.3%, OR = 0.49, 95% CI: 0.19 ~ 1.28, Z = 1.46, P > 0.05) by random effect model ($X^2 = 3.81, df = 1, P = 0.05, I^2 = 77$%). See Fig. 6.

**Discussion**

Rapid-cycling bipolar disorder represents a frequent severe subtype of illness which has been associated with poor response to pharmacological treatment. To our knowledge, this is first meta-analysis of lamotrigine and lithium combination in treatment for RCBD, which conclude 5 studies of only two randomized, parallel-group, placebo-controlled trials to evaluate the efficacy of a triple medication combination in RCBD [6,7] in English and of only three randomized controlled trial in Chinese [19,20,21]. The 2 studies in English are controlled study to evaluate the role of lamotrigine in combination with lithium and divalproex in presentations of RCBD not accompanied by a co-occurring substance use disorder, which in fact are treatment-resistant RCBD.

4 of the 5 studies with 185 subjects were included for the meta-analysis of response rate, which was 54.9% in study group and 45.7% in control group. 3 of the 5 studies with 145 subjects were included for the meta-analysis of remission rate, which was 47.9% in study group and 45.9% in control group. There was no difference both in response and remission. But the lamotrigine and lithium combination play role on more improving mental symptoms, especially in psychotic symptom rather than depressive and manic symptom, compared to control group. But subgroup meta-analysis show that lamotrigine and lithium combination had higher response rate compared to monotherapy of lithium in patients with no TR-RCBD. This result also show that lamotrigine and lithium combination can play important role in treatment of RCBD, especially in patient with no-TR-RCBD, which may suggest that the patients with no-TR-RCBD should been treated with lamotrigine and lithium combination.

The controlled study about treatment of RCBD indeed are less. The search returned 206 papers and ultimately 25 papers were selected for review [22]. Only six randomized, controlled trials specifically designed to study a rapid cycling population were found. Most data were derived from post hoc analyses of trials that had included rapid cyclers. The literature find that: (i) most patients with rapid cycling patients perform worse in the follow-up period; (ii) lithium have same efficacy comparable anticonvulsants; (iii) there is inconclusive evidence on the comparative acute or prophylactic efficacy of the combination of anticonvulsants versus anticonvulsant monotherapy; (iv) antipsychotic, such as aripiprazole, olanzapine, and quetiapine are effective against acute bipolar episodes; (v) olanzapine and quetiapine appear to be equally effective to anticonvulsants during acute treatment; (vi) aripiprazole and olanzapine appear promising for the maintenance of response of rapid cyclers; and (vii) presence of rapid cycling might be an association with antidepressant use. According this review and this study result, atypical antipsychotic maybe relative better selection for treatment of RCBD, although lamotrigine and lithium combination show better improvement mental symptoms and higher response in no-TR-RCBD. Other therapeutic was also useful selection, such as Vagus nerve stimulation (VNS) [23], levothyroxine augmentation therapy [24].

According to monotherapy, lamotrigine are similar to lithium in treatment of patients with RCBD in a small sample trial [25]. Also according to monotherapy, both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, $P = .02$; lithium vs placebo, $P = .006$). Lamotrigine was superior to placebo at prolonging the time to a depressive episode ($P = .02$). Lithium was superior to placebo at prolonging the time to a manic, hypomanic, or mixed episode ($P = .006$) [26]. It was obvious that study about
combination of lamotrigine and lithium in treatment for RCBD should be carried out. It was pity there were few clinical trials about combination of lamotrigine and lithium in treatment for RCBP. Update now, only the 5 study trial were found. So this meta-analysis was seen as a supplement of few trial. In fact, the combination study was proved to super to monotherapy of lithium for RCBD.

This study had several limitations. Firstly, the sample size of this meta-analysis was relatively small. Only 5 studies and 265 subjects were involved. Secondly, collecting data style may influence the result of investigation, for example, different criteria of RCBD can get different response. The different response and remission was found between no TR and TR patients. Thirdly, the dose and level in blood of drug was not cared. Fourth, the side effects related to drug, especially to combination therapy of lamotrigne and lithium. Fifth, not all the studies had blind observation. These factors are partly responsible for the source of pool response and remission rate of the study, also affect us to see the real significance of their combination.

**Abbreviations**

EMBASE=Excerpta Medical Database  
CBM=Chinese Biomedical Database  
CNKI=China National Knowledge Infrastructure  
CSSCI=Chinese Social Sciences Citation Index (VIP)  
YMRS=Yung Manic Rating Scale  
BRMS=Beck-Rafaelsdn Mania Rating Scale  
SPSS=Statistic product and service solutions  
PANSS=positive and negative symptom scale  
BPRS=Brief Psychotic Rating Scale  
TR=treatment-resistant  
RR=relative risk  
BD=bipolar disorder  
CI=confidence interval  
MADRS=Montgomery-Asberg Depression Rating Scale  
CGI=Clinical Global Impression

**Declarations**

1. Ethics approval and consent to participate  
Not Available  
2. Consent to publication
All authors agree to publish our paper and no conflict in any interests.

3. Availability of data and material.

See Table1

4. Competing interests

There were not any financial and non-financial competing interests.

5. Funding

Not Available

6. Author's contribution

All authors have read and approved the manuscript

Our authors have different contributions to this article. Dr GZH participated in collection of data and the writing of the article, Dr GZH, Dr LWQ and Dr SFL assessed the quality of researched papers. Dr SD and Dr SFL complete most statistic analysis. All authors reviewed researched whole paper. Prof JWD participated in the design, statistical processing and final revision of the article.

7. Acknowledgment

We thank Prof Wang Zhiqiang (Tsinghua University) give us study idea and Dr Xv Songquan (Zhejaing Province Mental Health Work Office) help us in literature retrieval. We thank Ms Ren Xin (Zhejaing Province Mental Health Work Office) and Dr Tao Hejian (Zhejiang Chinese Medical University) help us in part of statistic. We thanks Prof Fang Marong (Zhejiang University) in final revision of the article.

References

1. André F Carvalho, Dimos Dimellis, Xenia Gonda, Eduard Vieta, Roger S McIntyre, Konstantinos N Fountoulakis. Rapid cycling in bipolar disorder: a systematic review. J Clin Psychiatry. 2014;75(6):e578-86. doi: 10.4088/JCP.13r08905.

2. Kathrin Wilk, Ulrich Heger. Time of mood switches in ultra-rapid cycling disorder: a brief review. Psychiatry Res. 2010 Nov 30;180(1):1-4. doi: 10.1016/j.psychres.2009.08.011.

3. Kathrin Wilk, Ulrich Heger. Time of mood switches in ultra-rapid cycling disorder: a brief review. Psychiatry Res. 2010;180(1):1-4. doi: 10.1016/j.psychres.2009.08.011.

4. Rebecca Tillman, Barbara Geller. Definitions of rapid, ultrarapid, and ultradian cycling and of episode duration in pediatric and adult bipolar disorders: a proposal to distinguish episodes from cycles. J Child Adolesc Psychopharmacol, 2003;13(3):267-71. doi: 10.1089/104454603322572598.

5. Gao Zhihan, Jin Weidong. Antidepressants and Switch. Sichuan Mental Health, 2015, 28(1):14-17, doi:10.11886/j.issn.1007-3256.2015.01.005

6. Zuowei Wang, Keming Gao, David E Kemp, Philip K Chan, Mary Beth Serrano, Carla Conroy, Yiru Fang, Stephen J Ganocy, Robert L Findling, Joseph R Calabrese. Lamotrigine adjunctive therapy to lithium and divalproex in depressed patients with rapid cycling bipolar disorder and a recent substance use disorder: a 12-week, double-blind, placebo-controlled pilot study. Psychopharmacol Bull. 2010;43(4):5-21.
7. David E Kemp, Keming Gao, Elizabeth B Fein, Philip K Chan, Carla Conroy, Sarah Obral, Stephen J Ganocy, Joseph R Calabrese. Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder. Bipolar Disord. 2012, 14(7):780-9. DOI: 10.1111/bdi.12013

8. Jin Rui, Chen Fengpei, Zhu Jianfeng, Gao Zhihan, Shen Ying, Chen Zhengxin, Ren Zhibin, Ma Yongchun, and Jin Weidong. Lithium carbonate and lamotrigine for treatment of bipolar depression: which is better? Results from Chinese data in meta-analysis. EC Psychology and Psychiatry, 2018, 7(12):992-1002

9. Solmi M, Veronese N, Zaninotto L, van der Loos ML, Gao K, Schaffer A, Reis C, Normann C, Anghelescu IG, Correll CU. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr. 2016, 21(5):403-418.

10. Oruch R, Elderbi MA, Khattab HA, Pryme IF, Lund A. Lithium: a review of pharmacology, clinical uses, and toxicity. Eur J Pharmacol. 2014; 740:464-73. doi: 10.1016/j.ejphar.2014.06.042.

11. Weidong Jin, Maria Uscinska, Yongchun Ma. Review of double mood stabilizer treatment for bipolar disorder in China. Open Journal of Psychiatry, 2014, 4:1-4, http://dx.doi.org/10.4236/ojpsych.2014.41001

12. Zhu JF, Jin WD, Jin R, Ma YC and Ren ZB. Comparison of lithium and valproate concentration in serum during three different patients treated by lithium carbonate, sodium valproate and their combination: A preliminary study. Neuroscience and psychiatry, 2018, 1(1):1-5.

13. Sun Fengli, Chen Fengpei, Zhu Jianfeng, Gao Zhihan, Shen Ying, Chen Zhengxin, Ren Zhibin, Jin Rui, Ma Yongchun and Jin Weidong. The role of lithium carbonate in concept of double mood stabilize for treatment of bipolar mania. International Journal of Psychiatry Research. 2019, 2(1):1-6.

14. Wang Zhiqiang, Wen Lu, Ren Xin, Jin Weidong. Meta-analysis of clinical effects and switching rate of lamotrigine and antidepressants in treatment of bipolar depression. Sichuan Mental Health, 2015, 28(1):11-14, doi:10.11886/j.issn.1007-3256.2015.01.004

15. J R Calabrese 1, D J Rapport, E A Youngstrom, K Jackson, S Bilali, R L Findling. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder, European Psychiatry, 2005, 20(2), 92 - 95 DOI: https://doi.org/10.1016/j.eurpsy.2004.12.003.

16. Felipe Filardi da Rocha, Flávia Mello Soares, Humberto Correa, Antônio Lúcio Teixeira. Addition of lamotrigine to valproic acid: a successful outcome in a case of rapid-cycling bipolar affective disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Oct 1;31(7):1548-9. doi: 10.1016/j.pnbp.2007.06.012.

17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–2012. doi: 10.1001/jama.283.15.2008.

18. Celiac Disease. Rockville: Agency for Healthcare Research and Quality (US); 2004. [https://www.ncbi.nlm.nih.gov/books/NBK35149/].

19. Liu Jie, Han Haibin. Observation for the effect of lithium carbonate combined with lamotrigine on rapid-circulation bipolar disorder. China Health Vision, 2020, 4:4

20. Cai Ruifang. Clinical observation of combination of lithium carbonate and lamotrigine in treatment for patients with rapid-circulation bipolar disorder. Frontier in Medicine, 2012, 22(2):174-175.

21. Chen Chao, Pan Yan, Liu Xuebin, Cai Lirong, Dun Lianghua. The efficacy of lamotrigine combined with thium carbonate on rapid cycling bipolar disorder, Neurological Disease and Mental Health, 2006, 6(4):257-258.

22. Konstantinos N Fountoulakis, Dimitrios Kontis, Xenia Gonda, Lakshmi N Yatham. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord. 2013 Mar;15(2):115-37. doi: 10.1111/bdi.12045.
23. Husam Kayyali, Sherouk Abdelmoity, Lalit Bansal, Christian Kaufman, Kyle Smith, Erin Fecske, Kailash Pawar, Ara Hall, Megan Gustafson, Ayman Abdelmoity, Ahmed Abdelmoity. The Efficacy and Safety of Rapid Cycling Vagus Nerve Stimulation in Children With Intractable Epilepsy. Pediatr Neurol. 2020;109:35-38. doi: 10.1016/j.pediatrneurol.2020.04.003.

24. Pao-Huan Chen, Yu-Jui Huang. Remission of classic rapid cycling bipolar disorder with levothyroxine augmentation therapy in a male patient having clinical hypothyroidism. Neuropsychiatr Dis Treat. 2015;11:339-42. doi: 10.2147/NDT.S76973.

25. J Walden, L Schaerer, S Schloesser, H Grunze. An open longitudinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilization. Bipolar Disord. 2000;2(4):336-9. doi: 10.1034/j.1399-5618.2000.020408.x.

26. Charles L Bowden, Joseph R Calabrese, Gary Sachs, Lakshmi N Yatham. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392-400. doi: 10.1001/archpsyc.60.4.392.

### Table

**Table 1**

| Author(year) | Study design | Experimental group(EG) cases | Drugs of EG | Control group(CG) cases | Drugs of CG | Quality score | Index for Therapeutic Effect |
|--------------|--------------|------------------------------|-------------|-------------------------|-------------|---------------|------------------------------|
| Chen(2006)   | Comparison   | 20                           | Lithium+lamotrigine | 20          | lithium   | 8             | Response rate PANSS,BPRS     |
| Wang(2010)   | Comparison   | 18                           | Lithium+Valproate+lamotrigine | 18          | Lithium+Valproate | 8             | Response rate Remission rate YMRS,MADRS CGI |
| Kemp(2012)   | Comparison   | 23                           | Lithium+Valproate+lamotrigine | 26          | Lithium+Valproate+Placebo | 8             | Response rate Remission rate YMRS,MADRS CGI |
| Cai(2012)    | Comparison   | 30                           | Lithium+lamotrigine | 30          | lithium   | 8             | Response rate Remission rate |
| Liu(2020)    | Comparison   | 40                           | Lithium+lamotrigine | 40          | lithium   | 8             | PANSS,BPRS                   |

PANSS = positive and negative symptom scale; BPRS = Brief Psychotic Rating Scale; BPRS; YMRS = Yung Manic Rating Scale; MADRS = Montgomery-Asberg Depression Rating Scale; CGI = Clinical Global Impression

### Figures
Figure 1

Flowchart of selection of studies for inclusion in meta-analysis
Comparison of different mental symptom between study and control group. The comprehensive analysis show that study group had significant lower score of mental symptoms than that of control group(Z=2.34, P=0.02) by random model(X²=33.02, df=7, P<0.01). But these differences only were shown in PANSS(Z=5.18, P<0.01) and BPRS(Z=3.08, P<0.01), not shown in MADRS(Z=0.39, P>0.05) and YMRS(Z=0.94, P>0.05).
The funnel plot analysis of mental symptom The publishing bias was found by the funnel plot analysis.

| Study or Subgroup | STUDY Events | Total | Control Events | Total | Weight | Odds Ratio M-H, Fixed, 95% CI |
|-------------------|--------------|-------|----------------|-------|--------|-----------------------------|
| CAI2012           | 28           | 30    | 21             | 30    | 16.9%  | 2.79 [0.75, 10.33]          |
| CHEN2006          | 15           | 20    | 6              | 20    | 9.1%   | 7.00 [1.74, 28.17]          |
| KEMP2012          | 2            | 23    | 10             | 26    | 51.8%  | 0.15 [0.03, 0.79]           |
| WANG2010          | 7            | 18    | 6              | 18    | 22.2%  | 1.27 [0.33, 4.97]           |
| **Total (95% CI)**| **50**       | **91**| **43**         | **94**| 100.0% | 1.47 [0.79, 2.73]           |

Heterogeneity: Chi² = 13.02, df = 3 (P = 0.005); I² = 77%
Test for overall effect: Z = 1.21 (P = 0.22)

The comparison of response rate between study and control group. The random effect model was used for this analysis(X²=13.02,df=3, P<0.01, I² = 77%). The no difference in response rate was found between two groups(OR=1.47,95% CI: 0.79~2.73, Z=1.21,P> 0.05).
Figure 5

The comparison of remission rate between study and control group. 3 of the 5 studies with 145 subjects were included for the meta-analysis of remission rate, which was 47.9% in study group and 45.9% in control group. The random effect model was used for this analysis ($X_2=4.42$, df=2, $P>0.05$, $I^2=55\%$). The no difference in remission rate was found between two groups (OR=1.05, 95% CI: 0.49~2.25, $Z=0.13$, $P>0.05$).

Figure 6

Subgroup analysis of response between study and control group. Subgroup meta-analysis for response rate also was made according to treatment-resistant or not. The response rate of lamotrigine and lithium combination was significant higher compare to monotherapy of lithium in patients with no treatment-resistant (82% vs 54%, OR=4.26, 95% CI: 1.65~10.99, $Z=3.99$, $P<0.01$) by fixed effect model ($X_2=0.89$, df=1, $P>0.05$, $I^2=0\%$). But the response rate of lamotrigine, lithium and valprorat combination was not significant higher compare to placebo, lithium and valprorate combination in patients with treatment-resistant (21.9% vs 36.3%, OR=0.49, 95% CI: 0.19~1.28, $Z=1.46$, $P>0.05$) by random effect model ($X_2=3.81$, df=1, $P=0.05$, $I^2=77\%$).